Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 21, 2008
USP Opens Site in Brazil
Author(s)Pharmaceutical Technology Editors
The US Pharmacopeial Conventional added to its international sites with the official opening of its facility in Sao Paulo, Brazil.
Advertisement
São Paulo, Brazil (Aug. 18)-The US Pharmacopeial Convention (USP) added to its international sites with the official opening of its 1800-m2 facility in São Paulo, Brazil. The office and laboratory space will provide local manufacturers with better access to USP’s publications, reference standards, and other services.
At the facility’s opening, Roger L. Williams, USP executive vice-president and CEO, said the new site “demonstrates USP’s commitment to ensuring the quality and safety of pharmaceuticals, dietary supplements, and food ingredients to everyone, regardless of geographic, economic, or political borders. As the world continues to focus on these issues, it is even more important for standards-setting bodies and governments to collaborate.”
USP says the new site will work with local organizations, including the National Health Surveillance Agency, the Brazilian Pharmacopeia, and Febrafarma, to help ensure the quality of medicines and food. “Our presence will benefit Brazilian manufacturers, government agencies, and ultimately patients in Brazil, the US, and the many countries to which Brazil exports,” said Flavio Vormittag, vice-president, international-Brazil at USP, who will oversee the facility.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement